Kristen Zakian1, Jing Qi1,
1Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, NY, United States; 2Radiology, Columbia University Medical School; 3Surgery, Memorial Sloan-Kettering Cancer Center; 4Medicine, Memorial Sloan-Kettering Cancer Center
Liver toxicity related to chemotherapy is a growing concern in the combination use of chemo agents. To evaluate the chemotherapy related liver steatosis, serial 1H MRS was applied to monitor hepatic triglyceride contents changes in 27 colorectal cancer patients during FOLFOX or FUDR/irinotecan treatment. Fat/fat+water ratio (FFW) measured from baseline and post treatment were compared in 17 patients who finished 12 cycle chemotherapy. 9 patients showed increased FFW greater than 15% compared to baseline, indicating chemotherapy associated steatosis. Serial 1H-MRS quantitatively evaluates the mobilization of liver fat, providing a more accurate way to detect chemo-associated steatosis.